Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Advertising Enforcement Highlighted By HHS Amid Drop In Citations

Executive Summary

HHS blog post details activity of US FDA's Office of Prescription Drug Promotion during a year in which the office has only issued one enforcement letter, continuing a downward trend.

Advertisement

Related Content

Advertising Enforcement: US FDA Content To Let Competitors 'Duke It Out,' Woodcock Says
Xtampza ER Warnings Can't Be Hidden Behind Table And Chairs, US FDA Tells Collegium
Rx Promotion Citations By US FDA Plummet; UCLA Webpage Elicits Final Letter Of 2017
FDA's Promotional Reviews Decline, But Says It's Only Part Of Job
Contrave TV Ad's Slimmed Down Adverse Events Draw FDA Rebuke
FDA’s Rx Promo Citations Rise Slightly In 2016; Investigational Drug Promos Scrutinized
FDA's Decline In Promotion Enforcement Highlighted By Celator Booth Letter

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS120773

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel